Back to Results

Haemonetics Corporation (HAE)

Featured in High-Momentum Stocks

Haemonetics Corporation is a healthcare equipment and supplies company focused on medical technology solutions for hospitals and specialty care settings in the United States and international markets. As an issuer of common stock listed on the NYSE under the ticker HAE, the company develops systems and software for plasma collection and donor management, including NexSys PCS, PCS2, NexLynk DMS and Donor360. Its broader portfolio also includes hemostasis testing systems such as TEG products and TEG Manager software, Cell Saver Elite+ blood recovery systems, and VASCADE closure products. Haemonetics additionally provides devices and related technologies used in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery and cancer surgery, along with fiber optic sensor solutions used in medical and industrial applications. The company sells through direct sales teams, distributors, clinical specialists and sales representatives. Haemonetics was founded in 1971 and is headquartered in Boston, Massachusetts.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NYSE-HAE
$123.39
4.1% Upside
Fair
$124.50
5.1% Upside
Fair
Great
0.0%
November 5, 2026
56.0x
6.4x
4.0x
5.392 B
6.341 B
17.9%
98.7%
4.7
302.4%
Valuation • Fair Value

Haemonetics Corporation (NYSE-HAE) Fair Value by Valuation Model

Review the available estimates for Haemonetics Corporation (NYSE-HAE), including DCF Fair Value, Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$123.39

Estimated upside of 4.1% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$153.36

Discounted cash flow valuation reference.

Ben Graham Formula Value

$23.48

Classic Ben Graham valuation formula reference.

Comps Fair Value

$98.41

Comparable-company valuation reference.

Analyst Price Target

$124.50

Analysts imply upside of 5.1%.

How to read these valuation models

Use the 6 available valuation references for Haemonetics Corporation (NYSE-HAE) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Haemonetics Corporation (NYSE-HAE)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

1.352 B

Current operating scale indicator.

Revenue Forecast

1.415 B

Forward revenue estimate.

EBITDA

358.8 M

Current operating profitability reference.

EBITDA Forecast

447.5 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Haemonetics Corporation (NYSE-HAE) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Haemonetics Corporation (NYSE-HAE)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

8

Relatively strong quality score.

Beneish M-Score

-2.81

No elevated caution signal from this screen.

Altman Z-Score

4.7

Relatively strong balance-sheet zone.

FCF / Net Income

302.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Haemonetics Corporation (NYSE-HAE). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Haemonetics Corporation (NYSE-HAE)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 5, 2026

Days to Earnings

12

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Haemonetics Corporation (NYSE-HAE), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Haemonetics Corporation (NYSE-HAE) Stock Forecast & Technical Outlook

Review Haemonetics Corporation (NYSE-HAE) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Haemonetics Corporation (NYSE-HAE) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Haemonetics Corporation (NYSE-HAE) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Haemonetics Corporation (NYSE-HAE) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Haemonetics Corporation (NYSE-HAE) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Haemonetics Corporation (NYSE-HAE) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Haemonetics Corporation (NYSE-HAE)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Haemonetics Corporation (NYSE-HAE) has a Strong Buy consensus, with 5 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 5
Hold 2
Sell 0
FAQ • Fast Investor Answers

Haemonetics Corporation (NYSE-HAE) Stock FAQ

Data-supported answers about Haemonetics Corporation (NYSE-HAE), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$123.39
Estimated upside 4.1%
Valuation Rating
Undervalued
Estimated upside of 4.1%
Analyst Target
$124.50
Implied upside 5.1%
Financial Health
Great
Current financial-health read

The current fair value estimate for Haemonetics Corporation (NYSE-HAE) is $123.39. This implies an estimated upside of 4.1% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 4.1% versus the current market price.

The available analyst price target for Haemonetics Corporation (NYSE-HAE) is $124.50. The analyst target implies estimated upside of 5.1%.

The current financial health read for Haemonetics Corporation (NYSE-HAE) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Haemonetics Corporation (NYSE-HAE) is November 5, 2026.

The latest available data indicates no current dividend yield for Haemonetics Corporation (NYSE-HAE).

The current P/E ratio listed for Haemonetics Corporation (NYSE-HAE) is 56.0x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Haemonetics Corporation is 5.392 B.

The current enterprise value listed for Haemonetics Corporation is 6.341 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Haemonetics Corporation is NYSE-HAE, and the stock is listed on NYSE.

Haemonetics Corporation (NYSE-HAE) is listed on NYSE.

The current debt-to-total-capital ratio listed for Haemonetics Corporation is 17.9%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Haemonetics Corporation is 98.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks View more on NYSE

Comparable companies from the same industry, limited to one security per issuer.

ABT NYSE Abbott Laboratories Fair Value Fair Market Cap 179.4 B
ISRG NASDAQ Intuitive Surgical Inc Fair Value Fair Market Cap 156.8 B
SYK NYSE Stryker Corporation Fair Value Fair Market Cap 117.8 B
MDT NYSE Medtronic PLC Fair Value Fair Market Cap 116.8 B
BSX NYSE Boston Scientific Corp Fair Value Undervalued Market Cap 66.215 B
BDX NYSE Becton Dickinson and Co Fair Value Undervalued Market Cap 54.18 B
EW NYSE Edwards Lifesciences Corp Fair Value Fair Market Cap 51.34 B
MDLN NASDAQ Medline Inc Fair Value Fair Market Cap 44.818 B
IDXX NASDAQ IDEXX Laboratories Inc Fair Value Fair Market Cap 44.147 B
RMD NYSE ResMed Inc Fair Value Fair Market Cap 35.562 B
ALC NYSE Alcon AG Fair Value Undervalued Market Cap 33.943 B
GEHC NASDAQ GE HealthCare Technologies Inc Fair Value Undervalued Market Cap 32.273 B
DXCM NASDAQ DexCom Inc Fair Value Undervalued Market Cap 29.411 B
PHG NYSE Koninklijke Philips NV ADR Fair Value Fair Market Cap 26.348 B
STE NYSE STERIS plc Fair Value Fair Market Cap 22.635 B
ZBH NYSE Zimmer Biomet Holdings Inc Fair Value Fair Market Cap 18.799 B
SOLV NYSE Solventum Corp Fair Value Fair Market Cap 14.539 B
BAX NYSE Baxter International Inc Fair Value Fair Market Cap 13.08 B
SNN NYSE Smith & Nephew SNATS Inc Fair Value Undervalued Market Cap 12.906 B
PEN NYSE Penumbra Inc Fair Value Fair Market Cap 12.778 B